Bausch & Lomb Corp (BLCO) Stock Analysis and Metrics

Bausch & Lomb

NYSE: BLCO

$16.17 ▲ +0.19 (+1.19%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap5.77 Bn

P/E-27.35

P/S1.11

Div. Yield0.00

ROIC (Qtr)0.04

Total Debt (Qtr)5.04 Bn

Revenue Growth (1y) (Qtr)9.41

Add ratio to table…

About

Bausch + Lomb is a leading global eye health company dedicated to protecting and enhancing the gift of sight for people around the world. The company develops, manufactures and markets a broad portfolio of approximately 400 products that span contact lenses, intraocular lenses, surgical systems and devices, vitamin and mineral supplements, lens care solutions, prescription eye medications and over the counter eye drops. Operating in roughly 100 countries, Bausch + Lomb functions as a fully integrated eye health business that serves the full lifecycle of vision care from birth through later life.

Revenue is generated primarily from the sale of products in the eye health therapeutic areas, including branded pharmaceuticals, generic pharmaceuticals, over the counter vitamin and supplement products, and medical devices such as contact lenses, intraocular lenses and ophthalmic surgical equipment. Additional revenue streams arise from alliance and service income, licensing and co promotion arrangements, and contract manufacturing fees. The company’s sales are made directly or indirectly to customers worldwide, with product mix driving both volume and pricing dynamics.

The company operates through the following segments.

• Vision Care: This segment encompasses the contact lens and consumer eye care businesses. It offers a wide range of contact lenses including daily disposable, frequent‑replacement and therapeutic lenses such as Bausch + Lomb INFUSE®, Biotrue® ONEday, PureVision®, SofLens® and Bausch + Lomb ULTRA®. The consumer eye care division provides lens‑care solutions (Biotrue®, Renu®, Boston®), over the counter eye drops (Lumify®, Soothe®, Artelac®, Alaway®, Mioclear®) and vitamin supplements (PreserVision®, Ocuvite®).

• Pharmaceuticals: This segment supplies postoperative treatment products and generic pharmaceuticals for various eye conditions including glaucoma, inflammation, ocular hypertension, dry eye and retinal diseases. Key branded products are MIEBO®, XIIDRA®, Vyzulta®, Lotemax®, Prolensa® and Minims®, complemented by a portfolio of generic ophthalmic formulations.

• Surgical: This segment provides medical‑device equipment, consumables and technologies for cataract, corneal, vitreous and retinal procedures. It includes intraocular lenses and delivery systems, phacoemulsification platforms, surgical instruments and devices such as Akreos®, AMVISC®, IC 8 Apthera®, Crystalens®, enVista® IOLs, Eyetelligence® Surgical Planning Software, Millennium®, Stellaris Elite® vision‑enhancement system, Synergetics®, ClearVisc®, StableVisc®, Storz® ophthalmic instruments, VICTUS® femtosecond laser, Teneo®, Eyefill® and Zyoptix®.

Bausch + Lomb holds a leading position in the global eye health market, competing against other large ophthalmology companies through its diversified product line and integrated development, manufacturing and commercial capabilities. Its competitive advantage stems from a broad portfolio that covers vision care, pharmaceuticals and surgical devices, supported by substantial research and development investment and a presence in approximately 100 countries.

The company serves a varied customer base that includes individual consumers, patients, eye care professionals such as optometrists and ophthalmologists, hospitals, surgical centers, distributors and retail outlets worldwide. Specific customer names are not disclosed in the filing.

Investment Thesis

▲ Bull case

Bausch + Lomb is positioned for sustained growth through a resilient and diversified portfolio that is capturing secular tailwinds in eye health, particularly in the dry eye and premium IOL segments, where the company is leveraging strong brand momentum and clinical differentiation to drive consistent revenue expansion. The Pharmaceutical segment delivered 12% constant currency revenue growth in Q1, led by Miebo’s 33% year-over-year increase and Xiidra’s 30% surge, both reflecting successful execution on a strategy to shift from adoption to profitability. This growth is not merely cyclical but structural, as the dry eye market remains underpenetrated from a prescription standpoint, and Bausch + Lomb’s dual-action approach—combining Miebo’s anti-evaporative mechanism with Xiidra’s anti-inflammatory properties—creates a defensible, complementary franchise that is gaining traction with prescribers and patients alike. The company’s confidence in sustaining low double-digit growth for Xiidra and continued scaling of Miebo beyond seasonal headwinds signals a durable foundation for Pharmaceuticals’ contribution to overall earnings power.
The Surgical segment, despite a soft Q1 due to temporary weather disruptions and lapping a strong prior-year comparison, is showing clear leading indicators of sequential improvement that the market may be underestimating, particularly in premium IOLs and system placements. enVista Envy sales grew 88% year-over-year in Q1, with U.S. system placements nearly tripling versus the prior year, positioning the company for robust pull-through revenue as procedures resume and the rebuilt U.S. surgical field force begins to deliver on its strategic reset. The global rollout of premium products—including Envy’s launch in Europe and upcoming Elios rollout—supports a sustained shift toward higher-margin offerings, with premium IOLs already representing 26% of U.S. Surgical sales, up from 19% a year ago. This mix shift, combined with the company’s investment in next-generation platforms like Project Halo for contact lenses and seeLYRA/seeNOVA for surgical equipment, indicates a multi-year pipeline of innovation that is not being fully priced into current expectations, especially as the Surgical business is expected to strengthen sequentially through 2026 and beyond.
Bausch + Lomb’s Vision Care segment is benefiting from underappreciated geographic and product diversification, with Daily SiHy contact lens growth at 23% constant currency in Q1 and international markets showing resilience despite macroeconomic softness in certain regions. The company’s strategy to launch the full portfolio of modalities—including toric and multifocal lenses—in markets outside the U.S. is a deliberate, multi-year initiative that mirrors its domestic success, where the complete SiHy lineup has driven outperformance. John Ferris highlighted that the company is seeing early signs of this approach working in Asia Pacific and Japan, where the Japanese business grew 4% year-over-year despite a flat-to-declining market, suggesting that Bausch + Lomb is gaining share even in challenged environments. This global expansion of its premium contact lens franchise, coupled with strong OTC dry eye growth—Artelac up 34% and Blink Triple Care preservative-free launching nationwide—creates a self-reinforcing cycle of brand loyalty, physician endorsement, and retail velocity that is driving consistent, market-beating growth in a category often perceived as mature.
The company’s financial discipline and operating leverage are translating into meaningful margin expansion that is ahead of guidance and underpinning a credible path to deleveraging, with Q1 adjusted EBITDA margin expanding 500 basis points year-over-year to 16.1% and adjusted SG&A margin improving by 340 basis points. This is not a one-time benefit but the result of enduring structural changes from the Vision ‘27 initiative, including simplified operating models, productivity gains in manufacturing and supply chain, and accountability-driven expense management. Management raised full-year 2026 revenue guidance by $45 million and adjusted EBITDA guidance by $10 million, reflecting confidence in sustaining momentum, and noted that adjusted EBITDA is expected to grow at nearly 3x the rate of revenue—a testament to the operating leverage being unlocked. With net leverage improving and a clear path to the 3.5x target by 2028, the company is building financial resilience that allows it to continue investing in R&D (up 17% in Q1) while delivering earnings growth, a balance that is critical for long-term value creation in a capital-intensive, innovation-driven sector like eye health.

Bausch + Lomb is positioned for sustained growth through a resilient and diversified portfolio that is capturing secular tailwinds in eye health, particularly in the dry eye and premium IOL segments, where the company is leveraging strong brand momentum and clinical differentiation to drive consistent revenue expansion. The Pharmaceutical segment delivered 12% constant currency revenue growth in Q1, led by Miebo’s 33% year-over-year increase and Xiidra’s 30% surge, both reflecting successful execution on a strategy to shift from adoption to profitability. This growth is not merely cyclical but structural, as the dry eye market remains underpenetrated from a prescription standpoint, and Bausch + Lomb’s dual-action approach—combining Miebo’s anti-evaporative mechanism with Xiidra’s anti-inflammatory properties—creates a defensible, complementary franchise that is gaining traction with prescribers and patients alike. The company’s confidence in sustaining low double-digit growth for Xiidra and continued scaling of Miebo beyond seasonal headwinds signals a durable foundation for Pharmaceuticals’ contribution to overall earnings power.
The Surgical segment, despite a soft Q1 due to temporary weather disruptions and lapping a strong prior-year comparison, is showing clear leading indicators of sequential improvement that the market may be underestimating, particularly in premium IOLs and system placements. enVista Envy sales grew 88% year-over-year in Q1, with U.S. system placements nearly tripling versus the prior year, positioning the company for robust pull-through revenue as procedures resume and the rebuilt U.S. surgical field force begins to deliver on its strategic reset. The global rollout of premium products—including Envy’s launch in Europe and upcoming Elios rollout—supports a sustained shift toward higher-margin offerings, with premium IOLs already representing 26% of U.S. Surgical sales, up from 19% a year ago. This mix shift, combined with the company’s investment in next-generation platforms like Project Halo for contact lenses and seeLYRA/seeNOVA for surgical equipment, indicates a multi-year pipeline of innovation that is not being fully priced into current expectations, especially as the Surgical business is expected to strengthen sequentially through 2026 and beyond.
Bausch + Lomb’s Vision Care segment is benefiting from underappreciated geographic and product diversification, with Daily SiHy contact lens growth at 23% constant currency in Q1 and international markets showing resilience despite macroeconomic softness in certain regions. The company’s strategy to launch the full portfolio of modalities—including toric and multifocal lenses—in markets outside the U.S. is a deliberate, multi-year initiative that mirrors its domestic success, where the complete SiHy lineup has driven outperformance. John Ferris highlighted that the company is seeing early signs of this approach working in Asia Pacific and Japan, where the Japanese business grew 4% year-over-year despite a flat-to-declining market, suggesting that Bausch + Lomb is gaining share even in challenged environments. This global expansion of its premium contact lens franchise, coupled with strong OTC dry eye growth—Artelac up 34% and Blink Triple Care preservative-free launching nationwide—creates a self-reinforcing cycle of brand loyalty, physician endorsement, and retail velocity that is driving consistent, market-beating growth in a category often perceived as mature.
The company’s financial discipline and operating leverage are translating into meaningful margin expansion that is ahead of guidance and underpinning a credible path to deleveraging, with Q1 adjusted EBITDA margin expanding 500 basis points year-over-year to 16.1% and adjusted SG&A margin improving by 340 basis points. This is not a one-time benefit but the result of enduring structural changes from the Vision ‘27 initiative, including simplified operating models, productivity gains in manufacturing and supply chain, and accountability-driven expense management. Management raised full-year 2026 revenue guidance by $45 million and adjusted EBITDA guidance by $10 million, reflecting confidence in sustaining momentum, and noted that adjusted EBITDA is expected to grow at nearly 3x the rate of revenue—a testament to the operating leverage being unlocked. With net leverage improving and a clear path to the 3.5x target by 2028, the company is building financial resilience that allows it to continue investing in R&D (up 17% in Q1) while delivering earnings growth, a balance that is critical for long-term value creation in a capital-intensive, innovation-driven sector like eye health.

▼ Bear case

Bausch + Lomb’s Pharmaceutical segment growth, while impressive in Q1, may be overstated due to temporary benefits from the CVS contract termination for Xiidra, which shifted the gross-to-net ratio from the high 70s to the low 70s, artificially inflating revenue growth without a corresponding increase in prescription volume. Management acknowledged that script growth for Xiidra is declining as a direct result of losing CVS coverage, and while they framed this as a deliberate pivot to revenue and profitability, the sustainability of low double-digit growth hinges on maintaining pricing power and formulary access in an increasingly competitive dry eye landscape. The company’s reliance on Miebo and Xiidra as dual anchors is risky given the emerging competition in the prescription dry eye space, and any slowdown in adoption or reimbursement headwinds could disproportionately impact earnings, especially since the segment’s growth is not yet fully detached from seasonality, with Q1 traditionally being the weakest quarter and the company acknowledging that the strong start may not persist throughout the year without continued execution in a volatile payer environment.
The Surgical segment’s recovery is contingent on the successful rebuild and productivity of the U.S. field force, a transition that carries near-term execution risk and may not yield the expected sequential improvement if market conditions remain challenging or if the new sales structure fails to gain traction with key accounts. Management cited weather-related disruptions and tough lapping as reasons for the soft Q1 performance, but the business still only grew 1% constant currency, lapping 11% growth in the prior year, and the reliance on leading indicators like system placements—while positive—does not guarantee near-term procedure volume or consumable pull-through. The premium IOL push, while promising, faces headwinds from reimbursement pressures in select markets and the fact that surgeons often wait for long-term outcomes before adopting new lenses, meaning the current 27% constant currency growth in premium IOLs may not be sustainable if clinical differentiation fails to translate into widespread uptake, especially as competitors like Alcon and Johnson & Johnson Vision continue to invest heavily in their own premium portfolios.
Vision Care growth, particularly in contact lenses, may be losing momentum as the market moderates globally, and the company’s dependence on Daily SiHy—while growing at 23%—could be masking weakness in other franchises, with Ultra lenses up only 3% and the overall contact lens business growing just 5% constant currency in Q1. John Ferris noted that the U.S. contact lens market is expected to grow only 4% to 5% in 2026, and while Bausch + Lomb aims to outperform, the strategy to launch additional modalities internationally is a multi-year effort that may not pay off soon enough to offset softness in Asia Pacific and Japan, where economic muting and consumer affordability pressures could persist. The OTC dry eye growth, while strong—Artelac up 34%—is also vulnerable to private-label competition and retail shelf space constraints, and the company’s claim of holding close to 70% of the U.S. redness relief market with LUMIFY may be nearing saturation, limiting further share gains without significant new investment or innovation.
The company’s financial outlook, while improved, contains embedded conservatism that may mask underlying fragility, particularly in the assumption that operating leverage will continue to expand at the current pace, with adjusted EBITDA growing at nearly 3x revenue growth—a rate that may not be sustainable if gross margin improvement stalls or if SG&A efficiencies plateau after the initial benefits of the Vision ‘27 initiative are realized. Management raised guidance cautiously, citing the need to “take one step at a time” and acknowledging macroeconomic variables like energy costs, inflation, and affordability concerns in key markets, yet the current leverage trajectory depends on continued mix shift toward higher-margin products and disciplined expense control, both of which face headwinds if revenue growth slows or if R&D investment needs to increase to maintain pipeline momentum. With CapEx weighted to the first half and cash flow generation expected to improve only in the second half, any near-term disruption in earnings could strain the company’s ability to fund both operations and strategic investments while progressing toward its leverage target, especially if interest expense remains elevated at approximately $365 million annually.

Bausch + Lomb’s Pharmaceutical segment growth, while impressive in Q1, may be overstated due to temporary benefits from the CVS contract termination for Xiidra, which shifted the gross-to-net ratio from the high 70s to the low 70s, artificially inflating revenue growth without a corresponding increase in prescription volume. Management acknowledged that script growth for Xiidra is declining as a direct result of losing CVS coverage, and while they framed this as a deliberate pivot to revenue and profitability, the sustainability of low double-digit growth hinges on maintaining pricing power and formulary access in an increasingly competitive dry eye landscape. The company’s reliance on Miebo and Xiidra as dual anchors is risky given the emerging competition in the prescription dry eye space, and any slowdown in adoption or reimbursement headwinds could disproportionately impact earnings, especially since the segment’s growth is not yet fully detached from seasonality, with Q1 traditionally being the weakest quarter and the company acknowledging that the strong start may not persist throughout the year without continued execution in a volatile payer environment.
The Surgical segment’s recovery is contingent on the successful rebuild and productivity of the U.S. field force, a transition that carries near-term execution risk and may not yield the expected sequential improvement if market conditions remain challenging or if the new sales structure fails to gain traction with key accounts. Management cited weather-related disruptions and tough lapping as reasons for the soft Q1 performance, but the business still only grew 1% constant currency, lapping 11% growth in the prior year, and the reliance on leading indicators like system placements—while positive—does not guarantee near-term procedure volume or consumable pull-through. The premium IOL push, while promising, faces headwinds from reimbursement pressures in select markets and the fact that surgeons often wait for long-term outcomes before adopting new lenses, meaning the current 27% constant currency growth in premium IOLs may not be sustainable if clinical differentiation fails to translate into widespread uptake, especially as competitors like Alcon and Johnson & Johnson Vision continue to invest heavily in their own premium portfolios.
Vision Care growth, particularly in contact lenses, may be losing momentum as the market moderates globally, and the company’s dependence on Daily SiHy—while growing at 23%—could be masking weakness in other franchises, with Ultra lenses up only 3% and the overall contact lens business growing just 5% constant currency in Q1. John Ferris noted that the U.S. contact lens market is expected to grow only 4% to 5% in 2026, and while Bausch + Lomb aims to outperform, the strategy to launch additional modalities internationally is a multi-year effort that may not pay off soon enough to offset softness in Asia Pacific and Japan, where economic muting and consumer affordability pressures could persist. The OTC dry eye growth, while strong—Artelac up 34%—is also vulnerable to private-label competition and retail shelf space constraints, and the company’s claim of holding close to 70% of the U.S. redness relief market with LUMIFY may be nearing saturation, limiting further share gains without significant new investment or innovation.
The company’s financial outlook, while improved, contains embedded conservatism that may mask underlying fragility, particularly in the assumption that operating leverage will continue to expand at the current pace, with adjusted EBITDA growing at nearly 3x revenue growth—a rate that may not be sustainable if gross margin improvement stalls or if SG&A efficiencies plateau after the initial benefits of the Vision ‘27 initiative are realized. Management raised guidance cautiously, citing the need to “take one step at a time” and acknowledging macroeconomic variables like energy costs, inflation, and affordability concerns in key markets, yet the current leverage trajectory depends on continued mix shift toward higher-margin products and disciplined expense control, both of which face headwinds if revenue growth slows or if R&D investment needs to increase to maintain pipeline momentum. With CapEx weighted to the first half and cash flow generation expected to improve only in the second half, any near-term disruption in earnings could strain the company’s ability to fund both operations and strategic investments while progressing toward its leverage target, especially if interest expense remains elevated at approximately $365 million annually.

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Instruments & Supplies

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ALC	Alcon Inc	33,163,703.85 Bn	498,335.12	3.14 Mn	4.16 Bn
2	ISRG	Intuitive Surgical Inc	119.67 Bn	37.90	0.00 Mn	-
3	BDX	Becton Dickinson & Co	43.92 Bn	37.38	0.00 Mn	17.28 Bn
4	MDLN	Medline Inc.	31.71 Bn	56.52	0.00 Mn	12.57 Bn
5	RMD	Resmed Inc	28.46 Bn	18.73	0.00 Mn	0.66 Bn
6	WST	West Pharmaceutical Services Inc	23.80 Bn	45.05	0.00 Mn	0.20 Bn
7	COO	Cooper Companies, Inc.	13.77 Bn	58.38	0.00 Mn	2.46 Bn
8	SOLV	Solventum Corp	13.63 Bn	9.51	0.00 Mn	5.08 Bn

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password